FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a pharmaceutical composition for treating diseases mediated by the cystic fibrosis transmembrane regulator ("CFTR"), wherein the composition comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound by the formula
EFFECT: produced is a new pharmaceutical composition usable for treating diseases mediated by the cystic fibrosis transmembrane regulator ("CFTR").
1 cl, 7 tbl
Title | Year | Author | Number |
---|---|---|---|
HETEROCYCLIC MODULATORS OF ATP-BINDING CARTRIDGE TRANSPORTER | 2006 |
|
RU2463303C2 |
HETEROCYCLIC MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | 2012 |
|
RU2608610C2 |
MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | 2008 |
|
RU2512682C2 |
MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | 2007 |
|
RU2459821C2 |
METHODS AND INTERMEDIATE COMPOUNDS | 2010 |
|
RU2531588C2 |
MODULATORS OF ATP-BINDING CARTRIDGE TRANSPORTERS | 2012 |
|
RU2640420C2 |
PPAR-SUPPORTING COMPOUNDS FOR TREATING METABOLIC DISEASES | 2014 |
|
RU2687490C2 |
PPAR-SUPPORTING THIAZOLIDINEDIONES AND THEIR COMBINATIONS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | 2010 |
|
RU2570424C2 |
THIAZOLIDINEDIONE SALTS WITH REDUCED AFFINITY TO PPAR FOR TREATMENT OF METABOLIC DISORDERS | 2010 |
|
RU2564661C2 |
METHODS AND INTERMEDIATE PRODUCTS | 2006 |
|
RU2446171C2 |
Authors
Dates
2022-02-02—Published
2016-12-21—Filed